DCA Vantage Analyzer
Drive diabetic patient compliance with trusted, clinically proven results

DCA Vantage Analyzer
 
Purchase Options
DCA Vantage Analyzer

Watch animation

New 2-D barcode scanner.
New 2-D barcode scanner.
DCA Vantage Analyzer
Actionable results in 7 minutes or less

Minimize the need for follow-up visits with a full spectrum of results: HbA1c (NGSP certified and IFCC certified/CLIA waived), Estimated Average Glucose*, Albumin, Creatinine, and Albumin-to-Creatinine Ratio results.
*Not available in the US

DCA Vantage Analyzer
Easy to use in the office or clinic

No sample or reagent preparation is required, and the system provides versatile data management and reporting options

Robust technology delivers proven performance
Robust technology delivers proven performance

The analyzer leverages robust technology and delivers the proven performance of the DCA HbA1c and DCA Microalbumin/Creatinine tests highlighted in more than 140 clinical articles.

Manage diabetes testing in decentralized settings
Manage diabetes testing in decentralized settings

Powerful functionality enables POC coordinators to better manage diabetes testing in decentralized settings. When supported by Siemens RAPIDComm® Data Management System, coordinators can oversee and troubleshoot multiple connected analyzers in real time.

The DCA Vantage Analyzer is a point-of-care system that helps you monitor glycemic control and detect early kidney disease.

• CLIA-waived HbA1c test that is IFCC and NGSP-certified

• 1µl finger stick without fasting – HbA1c results in 6 minutes

• Random urine sample provides A:C ratio in 7 minutes

• Requires no sample or reagent preparation prior to testing

• New 2-D bar-code scanner — for the DCA Vantage® Analyzer and CLINIITEK Status® Connect System


Share this page:

Related Products, Services & Resources

References
1. Lenters-Westra E, Slingerland RJ. Clin Chem 2010;56(1):44.
2. Thaler LM, et al. Diabetes Care 1999;22:1415-21.
3. Miller CD, et al. Diabetes Care 2003;26:1158-63.
4. Cagliero E, et al. Diabetes Care 1999;22:1785-9.
5. GHX Market Intelligence, market data report. 4Q 2012 Report.